Table 6 Characteristics of the study sample of patients with and without LVH
From: Heart rate variability and target organ damage in hypertensive patients
| Â | LVH | P values | |
|---|---|---|---|
| Â | Patient Group with LVH | Patient group without LVH | Â |
Age (years) | 56.8 ± 12.1 | 66.3 ± 10.6 | 0.001 |
Sex (male/female) | 49/31 | 78/42 | 0.589 |
Family history of hypertension (yes/no) | 48/32 | 65/55 | 0.415 |
Family history of stroke (yes/no) | 15/65 | 24/96 | 0.827 |
Smokers (yes/ex/no) | 17/18/45 | 18/24/78 | 0.404 |
Diabetes (yes/no) | 2/78 | 18/102 | 0.004 |
Diastolic BP (mmHg) | 73.8 ± 12.1 | 76.8 ± 11.8 | 0.094 |
Systolic BP (mmHg) | 126.1 ± 25.3 | 137.9 ± 19.4 | 0.001 |
Pulse pressure (mmHg) | 52.3 ± 18.0 | 61.1 ± 16.8 | 0.001 |
Fasting blood glucose (mmHg) | 99.8 ± 23.6 | 104.7 ± 24.3 | 0.161 |
Total Cholesterol (mg/dl) | 191.0 ± 38.6 | 182.3 ± 41.7 | 0.132 |
BMI (kg/m2) | 27.2 ± 4.3 | 28.0 ± 4.8 | 0.235 |
Beta-blockers (yes/no) | 31/49 | 36/84 | 0.199 |
Alphabeta-blockers (yes/no) | 7/73 | 14/106 | 0.510 |
Alpha-blockers (yes/no) | 5/75 | 11/109 | 0.456 |
Diuretics (yes/no) | 25/55 | 62/58 | 0.004 |
ACE inhibitor (yes/no) | 25/55 | 50/70 | 0.136 |
Dihydropyridine (yes/no) | 17/63 | 35/85 | 0.211 |
eGFR (mL/min/1.73 m2) | 79.9 ± 17.9 | 75.1 ± 19.5 | 0.071 |
Kidney Involvement (1/2 /3) | 24/44/12 | 24/75/21 | 0.268 |
IMT (mm) | 1.82 ± 0.93 | 2.52 ± 1.82 | <0.001 |
Vascular abnormalities (no/ thickening/plaque) | 20/11/49 | 6/11/103 | <0.001 |
LVMi g/m2 | 105.0 ± 13.8 | 147.5 ± 27.3 | <0.001 |